Anavex Life Sciences Corp (AVXL)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Christopher U. Missling
Employees:
30
51 W 52ND STREET,, 7TH FLOOR, NEW YORK, NY 10019-6163
800-689-3939

Anavex Life Sciences Corp. engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the. treatment of Alzheimer's disease. The company's drug candidate also comprises ANaVEX 3-71 which is. in Phase I clinical. trial for frontotemporal dementia and other dementia indications.

Data derived from most recent annual or quarterly report
Market Cap 668.133 Million Shares Outstanding77.962 Million Avg 30-day Volume 1.278 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.17
Price to Revenue0.0 Debt to Equity0.0 EBITDA-55.214 Million
Price to Book Value5.3475 Operating Margin0.0 Enterprise Value578.956 Million
Current Ratio12.032 EPS Growth0 Quick Ratio11.647
1 Yr BETA 1.9782 52-week High/Low 15.24 / 7.13 Profit Margin0.0
Operating Cash Flow Growth-1.991 Altman Z-Score30.1586 Free Cash Flow to Firm -34.533 Million
Earnings Report2023-05-10
View SEC Filings from AVXL instead.

View recent insider trading info

Anavex Life Sciences Corp YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding AVXL (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AVXL

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2022-06-29 by VELDEN CLAUS VANDER
  • 4: filed on 2022-06-29 by THOMAS STEFFEN
  • 4: filed on 2022-06-29 by DONHAUSER PETER D.O.
  • 4: filed on 2022-06-29 by SKARPELOS ATHANASIOS
  • 4: filed on 2022-06-29 by MA JIONG
  • 4: filed on 2022-05-27 by SKARPELOS ATHANASIOS
  • 4: filed on 2021-08-04 by MA JIONG
  • 4: filed on 2021-08-04 by VELDEN CLAUS VANDER
  • 4: filed on 2021-08-04 by Boenisch Sandra
  • 4: filed on 2021-08-04 by DONHAUSER PETER D.O.

    • Events (8k)

  • 8-K: filed on 2023-03-13:
    Item 7.01: Regulation FD Disclosure
  • 8-K: filed on 2023-02-07:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-02:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-27:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-04-08:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-04:
    Item 4.01: Changes in Registrant's Certifying Accountant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-09-27:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-09-13:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-06-24:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-12-28:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    SKARPELOS ATHANASIOS

    • Director
    		 50,000 2022-06-27 2

    THOMAS STEFFEN

    • Director
    		 50,000 2022-06-27 1

    DONHAUSER PETER D.O.

    • Director
    		 50,000 2022-06-27 1

    VELDEN CLAUS VANDER

    • Director
    		 50,000 2022-06-27 1

    MA JIONG

    • Director
    		 50,000 2022-06-27 1

    MISSLING CHRISTOPHER U CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 500,000 2021-08-02 0

    BOENISCH SANDRA PFO AND TREASURER

    • Officer
    		 40,000 2021-08-02 0

    FAVUS ELLIOT

    • Director
    		 0 2021-05-21 0

    METZNER BERND

    • Director
    		 0 2016-09-22 0

    LALACH HARVEY PRESIDENT COO SECRETARY

    • Officer
    • Director
    		 1,118,572 2012-05-24 0

    TIDMARSH GEORGE F EXECUTIVE DIRECTOR

    • Officer
    • Director
    		 512,000 2012-02-09 0

    CHISHOLM JOHN ROBERT

    • Director
    		 0 2011-05-13 0

    LOWRY WILLIAM SEAN

    • Director
    		 0 2011-02-24 0

    DURRANT CAMERON EXECUTIVE CHAIRMAN

    • Officer
    • Director
    		 0 2011-02-03 0

    TOUSLEY DAVID L.

    • Director
    		 0 2010-09-01 0

    AYERS ALISON E.

    • Director
    		 0 2010-06-29 0

    KERGROHEN HERVE DE CEO

    • Officer
    		 0 2009-06-12 0

    WU PEI RU COO

    • Officer
    • Director
    • 10% Owner
    		 0 2006-04-25 0

    WU YANG PRESIDENT & CEO

    • Officer
    • Director
    • 10% Owner
    		 0 2006-04-25 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ANAVEX LIFE SCIENCES CORP AVXL 2023-03-31 22:15:04 UTC 3.7377 1.0823 150000
    ANAVEX LIFE SCIENCES CORP AVXL 2023-03-31 21:45:05 UTC 3.7377 1.0823 150000
    ANAVEX LIFE SCIENCES CORP AVXL 2023-03-31 21:15:03 UTC 3.7377 1.0823 150000
    ANAVEX LIFE SCIENCES CORP AVXL 2023-03-31 20:45:04 UTC 3.7377 1.0823 150000
    ANAVEX LIFE SCIENCES CORP AVXL 2023-03-31 20:15:04 UTC 3.7377 1.0823 150000
    ANAVEX LIFE SCIENCES CORP AVXL 2023-03-31 19:45:04 UTC 3.7377 1.0823 150000
    ANAVEX LIFE SCIENCES CORP AVXL 2023-03-31 19:15:04 UTC 3.7377 1.0823 150000
    ANAVEX LIFE SCIENCES CORP AVXL 2023-03-31 18:45:04 UTC 3.7377 1.0823 150000
    ANAVEX LIFE SCIENCES CORP AVXL 2023-03-31 18:15:04 UTC 3.7377 1.0823 150000
    ANAVEX LIFE SCIENCES CORP AVXL 2023-03-31 17:45:04 UTC 3.7377 1.0823 150000
    ANAVEX LIFE SCIENCES CORP AVXL 2023-03-31 17:15:03 UTC 3.7377 1.0823 150000
    ANAVEX LIFE SCIENCES CORP AVXL 2023-03-31 16:45:04 UTC 3.7427 1.0773 150000
    ANAVEX LIFE SCIENCES CORP AVXL 2023-03-31 16:15:04 UTC 3.7427 1.0773 150000
    ANAVEX LIFE SCIENCES CORP AVXL 2023-03-31 15:45:04 UTC 3.7427 1.0773 150000
    ANAVEX LIFE SCIENCES CORP AVXL 2023-03-31 15:15:03 UTC 3.7427 1.0773 250000
    ANAVEX LIFE SCIENCES CORP AVXL 2023-03-31 14:45:04 UTC 3.7427 1.0773 250000
    ANAVEX LIFE SCIENCES CORP AVXL 2023-03-31 14:15:04 UTC 3.7427 1.0773 250000
    ANAVEX LIFE SCIENCES CORP AVXL 2023-03-31 13:45:03 UTC 3.4725 1.3475 250000
    ANAVEX LIFE SCIENCES CORP AVXL 2023-03-31 13:15:03 UTC 3.4725 1.3475 250000
    ANAVEX LIFE SCIENCES CORP AVXL 2023-03-31 12:45:03 UTC 3.4725 1.3475 250000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    RUSSELL INVESTMENT FUNDS- U.S. Small Cap Equity Fund AVXL -1341.0 shares, $-12417.66 2022-12-31 N-PORT
    RUSSELL INVESTMENT CO- U.S. Small Cap Equity Fund AVXL -6131.0 shares, $-66643.97 2023-01-31 N-PORT

    Congressional Transactions Past 6-Months

    To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***
    Congress Person Party Chamber Filing Filing Date Transaction Date Security Type Owner Transaction Amount
    Hon. Christopher L. Jacobs republican House Filing 2023-01-10 2022-12-12 S $1,001-$15,000
    Hon. Christopher L. Jacobs republican House Filing 2022-11-11 2022-10-12 P $1,001-$15,000

    Elevate your investments